First Health Pharmaceuticals B.V. is a biotech company with its main offices in Amsterdam, the Netherlands. Considering the groundbreaking nature of the RNA Helicase targeting technology, developed by our group, and the vast array of pathogens and malignancies that is targeted by our compounds, it will come as no surprise that many research groups worldwide, directly or indirectly, participated in the research in our field of interest. Some of these collaborations are based on a joint development agreement but most academic groups performed efficacy tests related to pathogens that fit their field of research purely for academic reasons. These collaborations are of mutual benefit. Our research group is the only one in the world that developed a large portfolio of small molecule DDX3 Helicase inhibitors, for use both as antivirals and anti tumor agents. As such, many highly specialised research groups around the world are interested in testing our compounds, in order to gain more insight in the complex cellular RNA helicase biochemistry, related to the pathogens they are working on. We, from our side, also learn many new things about our field of research, but even in cases in which no direct benefit is to be expected for our company, we still aim to satisfy all requests that reach us from interested academic groups. Please visit our website for more information:http://firsthealthpharma.com/